Enliven Therapeutics ELVN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.18M+33.7% | $98.9M-2.8% | $101.73M-14.8% | $119.44M+17.4% | $101.71M-18.1% | ||
| $320.22M-12.0% | $363.73M-3.2% | $375.83M+1.3% | $371.07M+97.5% | $187.85M-0.8% | ||
| $463.14M-2.5% | $474.88M-1.6% | $482.68M-2.6% | $495.62M+68.4% | $294.32M-7.5% | ||
| $20K-41.2% | $34K-91.5% | $399K-13.6% | $462K+14.4% | $404K-11.8% | ||
| $464.85M-2.4% | $476.17M-3.0% | $490.88M-2.6% | $503.89M+66.5% | $302.57M-7.1% | ||
| $1.64M-24.0% | $2.16M+51.1% | $1.43M-39.2% | $2.35M+50.5% | $1.56M+16.4% | ||
| $11.49M-30.7% | $16.57M+13.1% | $14.65M-3.7% | $15.21M+8.9% | $13.97M-12.2% | ||
| $11.49M-30.7% | $16.57M+12.3% | $14.75M-4.3% | $15.42M+8.0% | $14.27M-10.3% | ||
| $61K+3.4% | $59K0.0% | $59K0.0% | $59K+20.4% | $49K0.0% | ||
| -$370.79M-6.8% | -$347.17M-9.3% | -$317.5M-6.8% | -$297.35M-9.3% | -$272.02M-11.7% | ||
| $453.37M-1.4% | $459.6M-3.5% | $476.12M-2.5% | $488.47M+69.4% | $288.3M-7.0% | ||
| $464.85M-2.4% | $476.17M-3.0% | $490.88M-2.6% | $503.89M+66.5% | $302.57M-7.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Enliven Therapeutics cover its short-term obligations?
- Its current ratio is 40.32 — current assets exceed current liabilities.
- Where does Enliven Therapeutics's balance sheet data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.